The first prognostic test for Crohn’s disease and ulcerative colitis

Award-winning PredictSURE IBD is the world’s first validated and CE-marked prognostic test for guiding treatment options in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). 

PredictImmune announced the start of the PRECIOUS (Predicting Crohn’s and Colitis Outcomes in the United States) study, which it is jointly funding with the Crohn’s & Colitis Foundation.

The PRECIOUS study is a multi-centre, observational study of patients with active Crohn’s disease or ulcerative colitis, who are not receiving systemic steroids, immunomodulators or biologics.

PRECIOUS study patients will be classified at diagnosis into high-risk and low-risk cohorts using PredictImmune’s PredictSURE IBD biomarker. PredictSURE IBD stratifies patients based on their risk of subsequently experiencing a severe disease course, which is characterised by the requirement for multiple escalations in treatment due to frequently relapsing or chronically active disease. The study will provide important data towards validation of PredictSURE IBD in a diverse patient population.

Caren Heller, MD, MBA, Chief Scientific Officer of the Crohn’s & Colitis Foundation, said“There is a critical need for improved biomarkers in IBD to advance us toward precision medicine and improving patient care. The validation of the PredictSURE IBD biomarker would be a great step toward the goal of treating the right patient, with the right therapy, at the right time.”

PredictSURE IBD is based on 10 years of extensive research into gene expression profiling of CD8+ T cells by researchers at Professor Ken Smith’s laboratory at the University of Cambridge, UK.

PredictImmune has entered into an exclusive commercial partnership with KSL Biomedical (KSL), to promote and provide PredictSURE IBD, throughout North America and French diagnostic specialist, Theradiag, to commercialise PredictSURE IBD in France, Belgium, Luxembourg, Switzerland and the Maghreb countries.

Both these announcements follow the successful launch of PredictSURE IBD in the UK and Ireland in April this year enabling better patient treatment in IBD.

You may also like Where credibility and trust go, clinicians follow.

Register FREE to access Health Industry Hub’s e-news bulletin; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and key stakeholders.